Preclinical evaluation of potential nilotinib cardiotoxicity-Reference-Cited by-同舟云学术

Preclinical evaluation of potential nilotinib cardiotoxicity

Published:2011-05 Issue:5 Volume:35 Page:631-637
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Wolf Armin,Couttet Philippe,Dong Min,Grenet Olivier,Heron Marcia,Junker Ursula,Ledieu David,Mahl Andreas,Marrer Estelle,Persohn Elke,Pognan Francois,Zhou Wei,Tsao Jeffrey,Roman Danielle

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Characterization of AMN107, a selective inhibitor of native and mutant bcr–abl;Weisberg;Cancer Cell,2005

2. AMN107 (nilotinib): a novel and selective inhibitor of BCR–ABL;Weisberg;Br J Cancer,2006

3. AMN107, a novel aminopyrimidine inhibitor of bcr–abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia;Golemovic;Clin Cancer Res,2005

4. TASIGNA® (nilotinib) capsules prescribing information,2007

5. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition;Force;Nat Rev Cancer,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications;Frontiers in Cardiovascular Medicine;2023-09-08

2. Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os;International Journal of Pharmaceutics;2023-03

3. AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia;Cancer Discovery;2021-06-08

4. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia;Current Hematologic Malignancy Reports;2020-02

5. Spontaneously occurring cardiovascular lesions in commonly used laboratory animals;Cardio-Oncology;2019-06-03